Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close. About Standard BioTools Inc.

Explore how evolving obesity research is shaping trial design, with a focus on precision, reproducibility, and clinical ...

Researchers at the Jacobs School of Medicine and Biomedical Sciences are leveraging a new National Institutes of Health (NIH) grant to advance their mechanistic insights into gut microbes.

One of Wall Street’s top firms just made the bull case for AbbVie (NYSE:ABBV | ABBV Price Prediction) stock, initiating ...

A type of rare T cell triggers a cascade of signals amplifying inflammation and ultimately leading to liver fibrosis, ...

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer ...

Bio-Rad Laboratories stock draws attention after trend movement. Explore drivers, sector position, and healthcare technology ...

The clinic offers treatment for several autoimmune and rheumatic conditions, including osteoporosis, rheumatoid arthritis, fibromyalgia and gout.

The human immunodeficiency virus (HIV), which is the cause of AIDS, is a master of deception, using just nine genes to hijack ...

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

Syed Yunis Bukhari In the evolving landscape of modern healthcare, much attention is given to advanced treatments, ...

April 22, 2026 expert reaction to Moderna / NIHR launch of new human vaccine trial: mRNA vaccine candidate against H5N1 bird flu . Scientists comment on the launch of a Moderna an ...